Yup, know that but ACER Therapeutics has many roads coming out of it and they are playing with various suitors. Not sure where they are with Sorrento with ABIVERTINIB but they do have enough cash to operate into 2H2021 so no rush on their part that I can see .
RELIEF THERAPEUTICS Holding AG
Under the terms of the Option Agreement, Acer will receive from Relief a $1 million non-refundable payment in return for exclusivity until June 30, 2021 to negotiate and enter into a definitive collaboration and license agreement between Acer and Relief for the development of ACER-001. Further, in connection with entering into the Option Agreement, Relief will make a $4.0 million loan to Acer. The loan, which will be secured by a lien on all of Acer's assets, will bear interest at the rate of 6% per annum and will be due in one year.
News 
Market Data 
Discover 
AI
